Publications of Robert Slany

Search


Robert Slany on Google Scholar

5 Key Publications

Garcia-Cuellar MP, Büttner C, Bartenhagen C, Dugas C, Slany R.K. (2016) Leukemogenic MLL-ENL fusions induce alternative chromatin states to drive a functionally dichotomous group of target genes. Cell Reports, pii: S2211-1247(16)30259-5. doi: 10.1016/j.celrep.2016.03.018

Bach C., and Slany R.K. (2014) DOTting the Path to Doom: How Acceleration of Histone Methylation Leads to Leukemia. Cancer Cell. 8;26(6):781-782.

Garcia-Cuellar M.P., Füller E., Maethner E., Breitinger C., Hetzner K., Zeitlmann L., Borkhardt A., and Slany R.K. (2014) Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed lineage leukemia, Leukemia, 28, 1427–1435 (doi: 10.1038/leu.2014.40)

Maethner E., Garcia-Cuellar M.P., Breitinger C., Takacova S., Divoky V., Hess J.L., and Slany R.K. (2013) MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells, Cell Reports, May 30;3(5):1553-66

Müller D., Garcia-Cuellar M.P., Bach C., Buhl S., Mäthner E., and Slany R.K. (2009) Misguided Transcriptional Elongation Causes Mixed Lineage Leukemia, PLOS Biology, 7(11):e1000249


Primary Publications(since 2012)

Wiersma M, Bussiere M, Halsall JA, Turan N, Slany R, Turner BM,  and Nightingale KP. (2016) Protein kinase Msk1 physically and functionally interacts with the KMT2A/MLL1 methyltransferase complex and contributes to the regulation of multiple target genes. Epigenetics Chromatin. 9:52.

Garcia-Cuellar MP, Büttner C, Bartenhagen C, Dugas C, Slany R.K. (2016) Leukemogenic MLL-ENL fusions induce alternative chromatin states to drive a functionally dichotomous group of target genes. CellReports, pii: S2211-1247(16)30259-5. doi: 10.1016/j.celrep.2016.03.018

Slany R.K. (2016) The molecular mechanics of mixed lineage leukemia, Oncogene, Review, Feb 29. doi: 10.1038/onc.2016.30

Nolte E, Sobel A, Wach S, Hertlein H, Ebert N, Müller-Uri F, Slany R, Taubert H, Wullich B, Kreis W. (2015) The New Semisynthetic Cardenolide Analog 3β-[2-(1-Amantadine)-1-on-ethylamine]-digitoxigenin (AMANTADIG) Efficiently Suppresses Cell Growth in Human Leukemia and Urological Tumor Cell Lines, Anticancer Res. 2015 Oct;35(10):5271-5.

Krumbholz M, Bradtke J, Stachel D, Peters O, Hero B, Holter W, Slany R, Metzler M. (2015) From initiation to eradication: the lifespan of an MLL-rearranged therapy-related paediatric AML. Bone Marrow Transplant. Oct;50(10):1382-4 doi: 10.1038/bmt.2015.155.

Woodcroft MW, Nanan K, Thompson P, Tyryshkin K, Smith SP, Slany R.K., LeBrun DP. (2015) Retrovirus-Mediated Expression of E2A-PBX1 Blocks Lymphoid Fate but Permits Retention of Myeloid Potential in Early Hematopoietic Progenitors. PLoS One. 10(6):e0130495. doi: 10.1371/journal.pone.0130495

Garcia-Cuellar M.P.,  Steger J., Füller E., Hetzner K, Slany R.K. (2015) Pbx3 and Meis1 cooperate through multiple mechanisms to support Hox-induced murine leukemia. Haematologica. Jul;100(7):905-913

Kaeda J., Ringel F., Oberender C., Mills K., Quintarelli C., Pane F., Koschmieder S., Slany R., Schwarzer R., Saglio G., Hemmati P., van Lessen A., Amini L., Greese M., Vagge E., Burmeister T., Serra A., Carson A., Schwarz M., Westermann J., Jundt F., Dörken B., le Coutre P. (2015) Upregulated MSI2 is associated with more aggressive leukemia. Leuk Lymphoma  Jan 23:1-9

Steger J., Füller, E., Garcia-Cuellar M.P., Hetzner K., and Slany R. K. (2015) Insulin like growth factor 1 is a direct HOXA9 target important for hematopoietic transformation, Leukemia,  Apr;29(4):901-908

Bach C., and Slany R.K. (2014) DOTting the Path to Doom: How Acceleration of Histone Methylation Leads to Leukemia. Cancer Cell. 8;26(6):781-782.
 
Füller E., Schäfer D., Fischer U., Krell P.F.I., Stanulla M., Borkhardt A. and Slany R. K. (2014) Genomic inverse PCR for exploration of ligated breakpoints (GIPFEL), a new method to detect translocations in leukemia, PLOSone, 9(8):e104419. doi: 10.1371/journal.pone.0104419

Garcia-Cuellar M.P., Füller E., Maethner E., Breitinger C., Hetzner K., Zeitlmann L., Borkhardt A., and Slany R.K. (2014) Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed lineage leukemia, Leukemia, 28, 1427–1435 (doi: 10.1038/leu.2014.40)

Maethner E., Garcia-Cuellar M.P., Breitinger C., Takacova S., Divoky V., Hess J.L., and Slany R.K. (2013) MLL-ENL inhibits polycomb repressive complex 1 to achieve efficient transformation of hematopoietic cells, CellReports, May 30;3(5):1553-66

Stein M.F., Lang S., Winkler T.H., Deinzer A., Erber S. Nettelbeck D.M., Naschberger E., Jochmann R., Stürzl M., Slany R.K., Werner T., Steinkasserer A., and Knippertz I. (2013)  Multiple IRF- and NFkB-sites cooperate in mediating cell type- and maturation-specific activation of the human CD83 promoter in dendritic cells. Mol. Cell. Biol. Apr;33(7):1331-44

Breitinger C., Maethner E., Garcia-Cuellar M.P., Schambony A., Fischer K.D., Schilling K. and Slany R.K. (2013) HOX genes regulate Rac1 activity in hematopoietic cells through control of Vav2 expression, Leukemia,27(1):236-238

Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J (2012) miR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia, PNAS, Nov 20;109(47):19397-402

Jiang X, Huang H, Li Z,  Li Y, Wang X, Gurbuxani S, Chen P, He C, You D, Zhang S, Wang J, Arnovitz S, Elkahloun A, Price C, Hong GM, Ren H, Kunjamma RB, Neilly MB, Matthews J, Xu M, Larson RA, Le Beau MM, Slany RK, Liu PP, Lu J, Zhang J, He C, and Chen J. (2012) Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 22: 524-535

Breitinger C., Maethner E., Garcia-Cuellar M.P., and Slany R.K. (2012) The homeodomain region controls the phenotype of HOX-induced murine leukemia. Blood, 120(19):4018-4027

Dassé E, Volpe G, Walton DS, Wilson N, Del Pozzo W, O'Neill LP, Slany RK, Frampton J, Dumon S. (2012) Distinct regulation of c-myb gene expression by HoxA9, Meis1 and Pbx proteins in normal hematopoietic progenitors and transformed myeloid cells. Blood Cancer J. 2(6):e76

Takacova S., Slany R., Bartkova J., Stranecky V., Dolezel P., Luzna P., Bartek J., Divoky V. (2012) DNA Damage Response and Inflammatory Signaling Limit the MLL-ENL induced
Leukemogenesis in vivo, Cancer Cell,21(4):517-531